You are here

MS-based Structural Proteomics for Drug Development and Design

Status: 
Past
Competition: 
New Technology Development
Sector: 
Health
Genome Centre(s):
Genome British Columbia
Project Leader(s):
Christoph Borchers (University of Victoria)
GE3LS: 
No
Fiscal Year Project Launched: 
2007-2008
Project Description: 

Proteins play a key role in important biological processes, and as such, are key targets for newly-developed drugs. The three-dimensional model of a protein can be analyzed to find promising sites for potential drug binding, a process called “rational drug design”. Determining the structure of a single protein typically takes months or even years using currently available techniques such as x-ray crystallography or nuclear magnetic resonance. The challenges these technologies face include the length of time required and that some key families of proteins (notably membrane receptors, which are often drug targets) may not be amenable to these types of analyses. Also, these techniques provide information about the most stable form of a protein, while the biologically active protein may take on a different shape while it interacts with other molecules as part of a biological process.

The sequencing of both the human genome and the genomes of several key pathogens has accelerated the pace at which potential protein drug targets are discovered. A recent study has estimated that 29% of proteins involved in binding to other proteins (“protein-protein interactions”) contain potential binding sites for small-molecule drugs. Since current screening processes do not easily detect these sites, this represents a vast, untapped resource of potential drug targets.

In order to speed up the drug design process and to take advantage of the possibilities presented by protein-protein interactions, this project will make use of techniques currently employed in the analysis of large numbers of proteins in a cell, tissue, or organism (“proteomics”). Specifically, emerging cross-linking techniques using formaldehyde and newly synthesized reagents will be employed to preserve biologically-active protein-protein interactions in living cells or in solution for subsequent analysis by mass spectrometry (MS). MS is an extremely sensitive and specific technique for determining chemical structures, and can provide comprehensive structural information about protein-protein interactions when used in combined with these cross-linking reagents.

Understanding these interactions can help assist in the development of potential lead drug candidates. Developing algorithms and software for the interpretation of the MS data in order to determine 3D structural models will be a major part of the project. We will utilize the solid foundation of existing modeling, prediction, calculation and database methods in order to achieve our goals. Our approach will be validated by the analysis of protein-protein interactions involved in a model system that is involved in the yeast cell cycle: the anaphase-promoting complex (APC). These tools and protocols will allow for the compilation of interaction data from 5 to 10 samples per day, and for analysis of three dimensional structures of protein families that are not easily studied by conventional techniques.

These tools will be adaptable to a variety of platforms, and should be of great value both to academic researchers seeking to understand the nature of biologically important proteins and to the pharmaceutical industry in the search for new therapeutics.

Outcomes: 

Drs. Borchers and Petrotchenko have also incorporated a spin-off company, called Creative Molecules, Inc. (www.creativemolecules.com), to distribute and commercialize the customized crosslinkers, photoprobes, and software packages developed during this project. The products offered are specifically designed to facilitate the characterization of protein tertiary structure and conformational changes, and protein interaction studies for drug design and development. These new reagents thus have the potential to impact structural studies in academia and industry by providing new insight into the function and regulation of proteins, signalling mechanisms in cellular processes involved in disease, and revealing novel drug targets for pharmaceutical development.

Since November 2008, Creative Molecules has had revenues of over $12,000 and has sold to several national and international academic and private-sector clients. Clients have expressed their appreciation for the products and services offered: for example, “Compliment to your cross-linkers! Excellent products” (Thomas Walzthoeni from the Institute of Molecular Systems Biology).

Potential avenues for economic growth also include a possible licensing agreement with a privately-held life sciences company that develops, markets, and sells innovative sample preparation products for the separation of proteins. The CEO of this company is particular interested in isotopically-coded cleavable crosslinkers and a potential commercial partnership with Dr. Borchers because “it is “an area where you have been quite active and innovative”. The Proteomics Centre and Protein Discovery have signed a mutual NDA and started to draft a term sheet with key points of a potential partnership.

We have also created and published three (3) webservers that make uniquely-developed protein structure tools freely available to researchers: (1) CS23D (www.cs23d.ca), a web server for rapidly generating accurate 3D protein structures using only assigned NMR chemical shifts as input; (2) Prosess (www.prosess.ca), a web server designed to evaluate and validate protein structures; and (3) GeNMR (www.genmr.ca), a web server for generating 3D protein structures using NOE-derived distance restraints and NMR chemical shifts. We have also generated the protein prediction and testing database (PPT-DB – www.pptdb.ca). In addition to supporting research in Canada, the public and international visibility of these resources contributes to establishing Canada as a world leader in protein structure research. It also supports Alberta’s (and Canada’s) leadership as a prion research centre.

Finally, five students were trained under this project in Dr. Borchers laboratory. One is now a Research Associate at UBC, and two are now in graduate school. The project also provided training and experience for three professionals in the Wishart laboratory, who will likely remain in Canada and continue to work on related projects.